The incidence and risk of osteoporosis in patients with anxiety disorder

A Population-based retrospective cohort study

Chen Hong-Jhe, MD, Kuo Chih-Yuan, MD, Tu Ming-Shium, MD, Wang Fu-Wei, MD, Chen Ru-Yih, MD, Hsieh Kuang-Chieh, MD, Pan Hsiang-Ju, MD, Chou Ming-Yueh, MD, Chen Pan-Ming, MD, Pan Chih-Chuan, PhD

Abstract
The purpose of this study was to investigate the relationship between anxiety disorder (AD) and the subsequent development of osteoporosis.

We conducted a population-based retrospective cohort analysis according to the data in the Longitudinal Health Insurance Database 2000 of Taiwan. We included 7098 patients in both the AD and no-anxiety cohort who were matched according to age and sex between January 1, 2000, and December 31, 2013. The incidence rate and the risk ratios (RRs) of subsequent new-onset osteoporosis were calculated for both cohorts. We used Cox proportional hazards models to assess the effect of AD. The Kaplan–Meier method was applied to estimate the cumulative osteoporosis incidence curves.

The AD cohort consisted of 7098 patients, and the comparison cohort comprised the same matched control patients without anxiety. The risk of osteoporosis was higher in the AD cohort than in the comparison cohort. In addition, the incidence of newly diagnosed osteoporosis remained significantly increased in all of the stratified follow-up durations (0–1, 1–5, 5–10, ≥10 years). Patients with AD were 1.79 times more likely to get osteoporosis than those without AD. We also observed a significant increase in osteoporotic risk in AD patients who are comorbid with hypertension, diabetes mellitus, and chronic liver disease.

The incidence of osteoporosis in Taiwan is associated with an a prior AD history. The risk ratios are the highest for osteoporosis within 1 year of AD diagnosis, but the risk remains statistically significant for >1 year. Clinicians should pay particular attention to osteoporotic comorbidities in AD patients.

Abbreviations: AD = anxiety disorder, RRs = risk ratios, BMD = bone mineral density, CRP = C-reactive protein, IL-6 = interleukin-6, TNF-α = tumor necrosis factor-α, NHI = National Health Insurance, NHIRD = National Health Insurance Database, ICD-9-CM = International Classification of Disease Ninth Revision Clinical Modification, LHID2000 = Longitudinal Health Insurance Database 2000, COPD = chronic obstructive pulmonary disease, HRs = hazard ratios, CI = confidence interval.

Keywords: anxiety disorders, epidemiology, osteoporosis, risk factors

1. Introduction

Anxiety disorder (AD) is one of the highly prevalent psychiatric diseases and is a major public health problem in many countries. AD causes unexpected or unhelpful anxiety that seriously affects people’s lives, including work, friendship, and thought, among others. AD is related to several disorders, such as panic, phobias, and generalized anxiety disorder. In the general population, the 12-month prevalence rates are approximately 18% for AD. AD has now been implicated in several chronic physical illnesses, including heart disease, hypertension, chronic respiratory disorders, and gastrointestinal conditions.

Osteoporosis is a silent disease caused by the systemic impairment of bone mass and microarchitecture, leading to increased probability of fractures of the vertebral, wrist, hip, and other skeletal bones. Osteoporosis is a chronic and worldwide medical condition, which is on the rise for ageing population and bad habits such as smoking and inactivity. The prevalence of osteoporosis in Taiwan was 1.63% in men and 11.35% in women. Osteoporotic fracture is the major complication of osteoporosis and its lifetime risk is within the range of 40% to 50% in women and 13% to 22% in men without medical intervention. The tremendously increased economic burden caused by osteoporotic fracture is also noted all over the world.
Increasing research has been conducted on the interplay between psychiatric disorders and osteoporosis. Studies suggest psychiatric disorders including depression, substance use disorder, anorexia nervosa, and schizophrenia may be risk factors for decreased bone mineral density (BMD).\cite{14-17}

However, few studies have been reported concerning the association between AD and osteoporosis.\cite{17} No epidemiologic study has investigated this relationship in Taiwan. Vogelzangs et al.\cite{18} found elevated inflammation is present in men with current AD. Persons with AD were considered as having chronic inflammation disease. Studies have correlated anxiety symptoms with increased C-reactive protein (CRP), amyloid-A, interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), white blood cell in relation to the anxious state.\cite{19} Compared with nonanxious cohort, 1 study showed anxious cohort had significantly lower levels of morning cortisol and significantly higher levels of IL-6.\cite{20}

There are lots of risk factors such as systematic inflammation been identified for osteoporosis and abnormal bone turnover.\cite{21} Chronic inflammation results in systemic bone loss, which is one of the mechanisms of osteoporosis.\cite{22} During inflammation, several growth factors and cytokines are increased inducing osteoclast differentiation and activation, and chronic inflammation is a condition that initiates systemic bone loss. One study showed that hip bone loss was found to be associated with raised baseline CRP and sacroiliitis diagnosed by magnetic resonance imaging.\cite{23} Another study found expression of activated nuclear factor-kappaB-inducing kinase in the osteoclasts lineage enhances the osteolytic response to inflammation.\cite{24} These inflammatory cytokines and chemokines activate immune cell recruitment and migration and may play a crucial role in the development of osteoporosis.

Therefore, we hypothesized that AD may play an essential role in the pathogenesis of osteoporosis. In response to the lack of national data and few longitudinal studies concerning the association between AD and the subsequent risk of osteoporosis, we designed a nationwide population-based study to investigate the incidence of osteoporosis among patients with AD.

2. Patients and methods

2.1. Data source

The National Health Insurance (NHI) program in Taiwan was instituted in 1995. In this compulsory program, comprehensive medical care coverage, including outpatient, inpatient, emergency, and traditional Chinese medicine, is offered to all residents, with a coverage rate up to 98%. The NHI Research Database (NHIRD) contains complete information regarding clinical visits, including prescription elements and diagnostic codes based on the A code and the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM). The NHIRD is managed and openly released for research purposes by the National Health Research Institutes, with confidentiality being maintained according to the directives of the Bureau of the NHI. The data source for this study was the Longitudinal Health Insurance Database 2000 (LHID 2000), which was constructed by systematic and random sampling from the NHIRD and includes the data of one million individuals. According to the Taiwanese National Health Research Institutes reports, no significant differences were observed for the distributions of age and sex or the average insured payroll-related amount between the data in the LHID 2000 and the original NHIRD.

2.2. Ethics statement

This study was approved by the Institutional Review Board of Taipei Veterans General Hospital (2013-03-035AC). Written consent was not obtained from the study participants because the data were obtained from the LHID 2000, which contains deidentified secondary data. In addition, the Institutional Review Board issued a formal written waiver for the need for consent.

2.3. Study population

In the present study, the data were extracted from the LHID 2000. First, we selected the patients with newly diagnosed osteoporosis from January 1, 2000 to December 31, 2013. Second, we excluded the patients with AD and those with osteoporosis between January 1, 1996, and December 31, 1999.

The definitions of AD and osteoporosis in the study were based on the ICD-9-CM codes (AD: 300.0X, 300.2X, 308.3X and osteoporosis: 733.0, 733.1). In addition, only patients who were diagnosed with AD by a psychiatrist were selected.

For each patient with AD included in the study cohort, a control patient without AD was matched for age and sex from the LHID 2000. We defined the first diagnosis date of AD as the index date for the both cohorts and all participants were observed until they were diagnosed with osteoporosis; or until death, withdrawal from the insurance system, or December 31, 2013.

2.4. Statistical analysis

The incidence of newly diagnosed osteoporosis in the AD and control cases was the primary outcome in this study. We compared the distributions of the demographic characteristics including common comorbidities between the 2 cohorts by using independent t tests for continuous variables and a χ² test for categorical variables. To investigate potential surveillance bias, subgroups were stratified according to the follow-up periods. Furthermore, a Cox proportional hazard regression model was used to calculate the hazard ratios (HR) of newly diagnosed osteoporosis in the AD and control cohorts.

We used the SAS statistical software for Windows, Version 9.3 (SAS Institute, Cary, NC) for all data processing and analyses. Some statistical analyses were performed using the SPSS software, Version 20 (IBM, Armonk, NY). P <0.05 was considered to be statistically significant.

3. Results

A total of 7098 patients with AD and 7098 age- and sex-matched patients without AD were selected in the present study (Table 1). The median follow-up duration was 10.79 and 10.87 years, separately. The 3 most common comorbidities among both cohorts were the same, including chronic liver disease, hypertension, and dyslipidemia. There were 573 patients diagnosed with osteoporosis in AD group during the follow-up duration. Patients with AD were more likely to be diagnosed with osteoporosis than those in the comparison cohort (IRR = 2.00, 95% confidence interval [CI] = 1.73–2.31) (Table 2). In addition, we performed a subanalysis based on the stratification of the follow-up duration, which revealed that the highest risk ratio for developing osteoporosis was within the first year after a AD diagnosis. However, it remains statistically significant for >1 year after AD diagnosis. Furthermore, most of the patients among both cohorts developed the subsequent osteoporosis during the follow-up duration of 1 to 5 and 5 to 10 years.
The Cox proportional hazard regression analysis was conducted to calculate the crude HR of the newly diagnosed osteoporosis for patients in the AD and control cohorts. In addition, multivariate analysis for adjusting the confounding factors between AD and osteoporosis was performed and the adjusted HR shown that the patients with AD still have higher risk of developing subsequent osteoporosis (adjusted HR = 1.79, 95% CI = 1.54–2.07) (Table 3 and Fig. 1).

We performed the Cox regression model again to detect potential risk factors for osteoporosis among the patients with AD. The results of the analysis indicated that the comorbidities of hypertension, diabetes mellitus, chronic obstructive pulmonary disease (COPD), and chronic liver disease may have higher risk for subsequent development of osteoporosis among the patients with AD (Table 4).

### Table 1
Baseline characteristics of patients with and without anxiety.

| Demographic data          | Patients with anxiety, n = 7098 | Patients without anxiety, n = 7098 | P       |
|---------------------------|---------------------------------|-----------------------------------|---------|
| Age, y^*                  | 37.23 (28.46–47.22)             | 37.23 (28.46–47.22)               | 0.999   |
| ≥50                       | 1370                            | 1370                              |         |
| <50                       | 5728                            | 5728                              |         |
| Sex                       |                                 |                                   |         |
| Male                      | 3218                            | 3218                              | 0.999   |
| Female                    | 3880                            | 3880                              |         |
| Comorbidities             |                                 |                                   |         |
| Depressive disorder       | 703                             | 56                                | <0.001  |
| Hypertension              | 1242                            | 816                               | <0.001  |
| Diabetes mellitus         | 740                             | 515                               | <0.001  |
| Dyslipidemia              | 995                             | 618                               | <0.001  |
| Cerebrovascular disease   | 570                             | 258                               | <0.001  |
| COPD                      | 741                             | 459                               | <0.001  |
| Nephropathy               | 690                             | 442                               | <0.001  |
| Autoimmune disease        | 203                             | 113                               | <0.001  |
| Obesity                   | 60                              | 22                                | <0.001  |
| Congestive heart failure  | 110                             | 65                                | <0.001  |
| Chronic liver disease     | 2241                            | 1320                              | <0.001  |
| Degree of urbanization    |                                 |                                   | <0.001  |
| Urban                     | 4518                            | 4461                              |         |
| Suburban                  | 2060                            | 2235                              |         |
| Rural                     | 520                             | 402                               |         |
| Income group              |                                 |                                   | 0.005   |
| High income               | 970                             | 916                               |         |
| Medium income             | 1340                            | 1509                              |         |
| Low income                | 3398                            | 3304                              |         |
| No income                 | 1390                            | 1369                              |         |
| Follow-up years^*         | 10.79 (9.57–12.31)              | 10.87 (9.67–12.34)                | <0.001  |

COPD = chronic obstructive pulmonary disease.
^*Median (interquartile range).

### Table 2
Incidence Rates of osteoporosis in patients with and without anxiety.

|                    | Patients with anxiety | Patients without anxiety | Risk ratio (95% CI) | P       |
|--------------------|-----------------------|--------------------------|---------------------|---------|
| No. of osteoporosis| 573                   | 291                      | 2.00 (1.73–2.31)    | <0.001  |
| Age, y             |                        |                          |                     |         |
| ≥50                | 295                   | 166                      | 1.87 (1.54–2.28)    | <0.001  |
| <50                | 278                   | 125                      | 2.01 (1.81–2.79)    | <0.001  |
| Sex                |                       |                          |                     |         |
| Male               | 137                   | 73                       | 2.16 (1.41–2.55)    | <0.001  |
| Female             | 436                   | 218                      | 5.28 (2.05–12.9)    | <0.001  |
| Follow-up          |                       |                          |                     |         |
| 0–1                | 79                    | 41                       | 2.33 (1.58–3.48)    | <0.001  |
| 1–5                | 219                   | 113                      | 1.51 (1.20–1.91)    | <0.001  |
| 5–10               | 212                   | 107                      | 1.94 (1.55–2.47)    | <0.001  |
| ≥10                | 63                    | 30                       | 2.17 (1.38–3.47)    | <0.001  |

^*=confidence interval.
Comorbidities

The results of our study showed that significantly higher risk of osteoporosis development among the patients with AD after adjustment for the potential confounding factors among both cohorts. In addition, older age, female sex, and several physical comorbidities including hypertension, diabetes mellitus, COPD, and chronic liver disease could be considered as risk factors for developing osteoporosis among the patients with AD. According to the results of our study, AD might be a risk factor for subsequent osteoporosis. We hypothesize that this may be attributable to several mechanisms. First, the development of osteoporosis may be the result of an inflammatory process caused by AD. Inflammation may play a role in AD and link to the association between AD and cardiovascular burden.[23] Studies have correlated anxiety symptoms with increased cytokine levels, in particular CRP.[19,26] Increased inflammatory cytokines and chemokines can affect osteoporosis. Inflammatory processes such as high-sensitivity CRP levels are evident association with high bone turnover rate and bone mass loss, which contributes to osteoporosis.[27] Bone remodeling is affected by several factors, including in AD and osteoporosis patients needs more investigation for further interpretation. Third, several researches found the association between cortisol level and osteoporosis patients may be the result of an inflammation de novo antioxidant enzymes (superoxide dismutase, glutathione peroxidase, and catalase) activity levels and malondialdehyde elevation in patients with anxiety such as social phobia. Clinical researches presented a raised lipid peroxidation, which was oxidative biomarker in patients with anxiety.[30] The association between cortisol level and osteoporosis patients may be the result of an inflammation de novo antioxidant enzymes (superoxide dismutase, glutathione peroxidase, and catalase) activity levels and malondialdehyde elevation in patients with anxiety such as social phobia.

![Figure 1](Image 109 to 309)

**Figure 1.** Cumulative incidence comparison of newly diagnosed osteoporosis for patients with (solid line) and without (dashed line) anxiety.

### Table 3

| Predictive variables | Univariate analysis | Multivariate analysis |
|----------------------|---------------------|-----------------------|
|                      | HR (95% CI)         | P         | HR (95% CI)         | P         |
| Anxiety              | 2.00 (1.74–2.30)    | <0.001    | 1.79 (1.54–2.07)    | <0.001    |
| Age (<50 = 0, ≥50 = 1) | 5.56 (4.86–6.36) | <0.001    | 4.90 (4.19–5.72)    | <0.001    |
| Sex (male = 0, female = 1) | 2.57 (2.20–3.00) | <0.001    | 3.49 (2.97–4.10)    | <0.001    |
| Comorbidities        |                     |           |                      |           |
| Depression           | 1.52 (1.18–1.96)    | <0.001    | 1.16 (0.90–1.51)    | 0.256     |
| Hypertension         | 3.39 (2.95–3.91)    | <0.001    | 1.40 (1.84–1.66)    | <0.001    |
| Diabetes mellitus    | 2.83 (2.39–3.35)    | <0.001    | 1.26 (1.04–1.52)    | 0.019     |
| Dyslipidemia         | 2.48 (2.11–2.91)    | <0.001    | 0.96 (0.80–1.16)    | 0.663     |
| Congestive heart failure | 2.76 (2.26–3.36) | <0.001    | 1.12 (0.91–1.39)    | 0.298     |
| COPD                 | 2.40 (2.01–2.87)    | <0.001    | 1.35 (1.12–1.63)    | 0.002     |
| Nephropathy          | 2.02 (1.66–2.44)    | <0.001    | 1.00 (0.82–1.23)    | 0.970     |
| Autoimmune disease   | 1.51 (1.03–2.21)    | 0.036     | 1.08 (0.73–1.59)    | 0.704     |
| Obesity              | 0.79 (0.30–2.12)    | 0.643     |                      |           |
| Congestive heart failure | 3.84 (2.68–5.49) | <0.001    | 1.10 (0.76–1.60)    | 0.622     |
| Chronic liver disease | 2.14 (1.87–2.45)  | <0.001    | 1.63 (1.41–1.89)    | <0.001    |
| Degree of urbanization |                   |           |                      |           |
| Urban                | Reference           |           |                      |           |
| Suburban             | 1.12 (0.97–1.30)    | 0.129     | 1.10 (0.95–1.27)    | 0.220     |
| Rural                | 1.55 (1.22–1.96)    | <0.001    | 1.20 (0.94–1.52)    | 0.144     |
| Income group         |                     |           |                      |           |
| High income          | Reference           |           |                      |           |
| Medium income        | 1.20 (1.01–2.50)    | <0.001    | 1.05 (0.81–1.37)    | 0.709     |
| Low income           | 1.68 (1.32–2.14)    | <0.001    | 1.22 (0.96–1.56)    | 0.112     |
| No income            | 1.13 (0.86–1.50)    | 0.386     | 1.02 (0.77–1.36)    | 0.867     |

CI = confidence interval. COPD = chronic obstructive pulmonary disease. HR = hazard ratio.
Income group

Comorbidities

Degree of urbanization

Comorbidities

Dyslipidemia

Chronic liver disease

Depressive disorder

Hypertension

Diabetes mellitus

Dyslipidemia

Cerebrovascular disease

COPD

Nephropathy

Autoimmune disease

Obesity

Congestive heart failure

Chronic liver disease

Degree of urbanization

Urban

Suburban

Rural

Income group

High income

Medium income

Low income

No income

Table 4
Analyses of risk factors for osteoporosis in patients with anxiety.

| Predictive variables                  | Univariate analysis | Multivariate analysis |
|--------------------------------------|---------------------|-----------------------|
|                                      | HR (95% CI)         | P                     |
|                                      |                     |                       |
| Age (<50 = 0, ≥50 = 1)               | 5.27 (4.47–6.21)    | <0.001                |
| Sex (male = 0, female = 1)           | 2.65 (2.19–3.21)    | <0.001                |
| Comorbidities                        |                     |                       |
| Depressive disorder                  | 1.18 (0.91–1.54)    | 0.207                 |
| Hypertension                         | 2.98 (2.52–3.54)    | <0.001                |
| Diabetes mellitus                    | 2.52 (2.06–3.08)    | <0.001                |
| Dyslipidemia                         | 2.12 (1.75–2.56)    | <0.001                |
| Cerebrovascular disease              | 2.10 (1.66–2.65)    | <0.001                |
| COPD                                 | 1.77 (1.41–2.21)    | <0.001                |
| Nephropathy                          | 1.50 (1.18–1.91)    | <0.001                |
| Autoimmune disease                   | 1.40 (0.90–2.16)    | 0.133                 |
| Obesity                              | 0.81 (0.30–2.17)    | 0.679                 |
| Congestive heart failure             | 3.07 (1.99–4.75)    | <0.001                |
| Chronic liver disease                | 1.85 (1.57–2.18)    | <0.001                |
| Degree of urbanization               |                     |                       |
| Urban                                | Reference           |                       |
| Suburban                             | 1.18 (0.98–1.41)    | 0.080                 |
| Rural                                | 1.40 (1.05–1.87)    | 0.022                 |
| Income group                          |                     |                       |
| High income                          | Reference           |                       |
| Medium income                        | 1.68 (1.38–2.57)    | <0.001                |
| Low income                           | 1.56 (1.17–2.09)    | 0.003                 |
| No income                            | 1.17 (0.84–1.64)    | 0.354                 |
| **CI**                               | **95% CI**          | **HR (95% CI)**       |
| **0.001**                            | **0.95 (0.64**      |
| **0.001**                            | **1.01 (0.64–1.60** |
| **0.001**                            | **0.86 (0.67–1.10** |
| **0.001**                            | **1.33**            |
| **0.001**                            | **1.04 (0.74–1.46** |
| O = confidence interval, COPD = chronic obstructive pulmonary disease, HR = hazard ratio.

social phobia and panic disorder. Total oxidant status and oxidative stress index were significantly higher in generalized AD than control group. The involvement of oxidative stress in the development of postmenopausal osteoporosis has recently been well documented. AD maybe implicated with osteoporosis by oxidative stress. Fourth, behavioral patterns typically associated with common psychiatric disorders, including increased cigarette smoking and alcohol, which have been shown to have negative effects on bone metabolism leading to osteoporosis. Fifth, lysophosphatidic acid (LPA), a water-soluble phospholipid derivative, plays an essential role in bone development and decreased bone mass. In addition, another study focused on LPA1 receptor also revealed that anxiety-like responses could be observed in LPA1 receptor knockout mice. Although it is difficult to explore the temporal relationship between the anxiety and osteoporosis based on these results, these studies on LPA may implicate a possible linkage between them, which is consistent with the results of our present study.

In our study, the result of multivariate analysis among the patients with AD revealed that comorbidities including hypertension, diabetes mellitus, and chronic liver disease could be seen as potential risk factors for the subsequent development of osteoporosis. Numerous epidemiological investigations show that patients with AD may have a higher risk of hypertension than those without AD and concluded that AD is associated with hypertension. Anxiety increases blood pressure, systemic vascular resistance, sympathetic activity, and plasma renin activity that contribute to the risk factors of hypertension. Hypertension has been demonstrated to be a risk factor for osteoporosis. In hypertension patients, excess urinary calcium secretion induces secondary parathyroidism to increase serum calcium level by calcium release from bone, which may accelerate osteoporosis. Based on the above-mentioned reason, comorbid hypertension in patients with AD might be more vulnerable to the pathophysiologic processes that contribute to osteoporosis.

Kai et al found AD is independently associated with the metabolic syndrome in a population at higher risk for type 2 diabetes mellitus. To cope with the influences from anxiety symptoms, patients place themselves at further risk for diabetes, such as more overeating. It is well known that type 1 diabetes mellitus increase vulnerability to bone microstructure. Type 2 diabetes mellitus increases trabecular defects and cortical porosity, and compromised bone mechanical properties. In addition, hyperglycemia and insulin resistance may further induce osteoblast apoptosis and diminished activities of osteoblasts, osteoclasts, and osteocytes. According to listed results of researches, diabetes mellitus may be considered a potential risk factor for osteoporosis especially among the patients with AD.

Anxiety-related psychological distress is associated with liver disease mortality and evidence has shown that possible mechanisms may be associated with the release of proinflammatory factors (eg, IL-6, TNF-α) caused by unhealthy behaviors, including alcohol intake, tobacco use, and poor diet habit. Osteoporosis is a complication of chronic liver disease. Chen et al found hepatitis B virus increases the risk of osteoporosis. Patients with ultrasound-defined nonalcoholic fatty liver disease had an increased independent risk of lower bone mass density. The mechanism included chronic inflammation and impaired osteoblast and overactive osteoclast in decompensated liver cirrhosis. We could postulate that chronic liver disease may indirectly result in osteoporosis among the patients with AD.

In our study, surveillance bias should be considered because patients with AD may have more possibilities to have frequent
climatic visits than the control patients, which may result in an earlier diagnosis of osteoporosis.[57] Therefore, we conducted a subgroup analysis by stratifying the follow-up periods among both cohorts. The results revealed that incident osteoporosis was still increased after the first year of a diagnosis of AD. Hence, we assumed that the increased risk of osteoporosis in AD patients would not be a results caused by surveillance bias totally. Although psychotropic agents, especially selective serotonin reuptake inhibitors (SSRIs) and benzodiazepines (BZDs), have been seen as risk factors of osteoporosis, patients with depressive disorders, which may have more possibilities to receive more SSRIs than those with AD, were included in the Cox regression model and the result of the multivariate analysis revealed that patients with AD, not depressive disorders, would have a higher risk of developing osteoporosis. In addition, there are still some studies which emphasized that SSRIs or BZDs should be seen as risk factors of osteoporotic fracture rather than of the development of osteoporosis.[58–61]

However, this study had several limitations. First, the NHIRD lacks essential data related to the primary outcome of the study, such as detailed demographic information of tobacco use, alcohol consumption, body mass index, socioeconomic status, and family history of osteoporosis. Therefore, we were unable to correlate osteoporosis with above-mentioned risk factors. Second, diagnostic delay of osteoporosis might occur in the study, which may indicate that the temporal relationship between the AD and the development of osteoporosis could not be confirmed in our study.

In conclusion, patients with AD may have elevated risk to develop osteoporosis. Moreover, in addition to the common risk factors of osteoporosis such as older age and female sex, hypertension, diabetes mellitus, COPD, and chronic liver disease may be considered as potential risk factors of osteoporosis, especially among the patients with AD. Further prospective epidemiological study on the relationship between AD and osteoporosis is warranted.

Acknowledgments
The authors thank the Research Center of Medical informatics at Kaohsiung Veterans General Hospital for technical assistance. The authors express their particular gratitude to the government organization BNHI and the nonprofit foundation NHRI.

References
[1] Reeves WC, Strine TW, Pratt LA, et al. Mental illness surveillance among adults in the United States. MMWR Surveill Summ 2011;60(Suppl 3):1–29.
[2] Bandelow B, Michaelis S. Epidemiology of anxiety disorders in the 21st century. Dialogues Clin Neurosci 2015;17:327–35.
[3] Tannos CY, Abou-Saleh MT, Karam AN, et al. The epidemiology of anxiety disorders in the Arab world: a review. J Anxiety Disord 2009;23:409–19.
[4] Demyyttenaar K, Brufaerts R, Posada-Villa J, et al. Prevalence, severity, and unmet need for treatment of mental disorders in the World Health Organization World Mental Health Surveys. JAMA 2004;291:2381–90.
[5] Kemp AH, Brunoni AR, Nunes MA, et al. The association between mood anxiety disorders, and coronary heart disease in Brazil: a cross-sectional analysis on the Brazilian longitudinal study of adult health (ELSA-Brasil). Front Psychol 2015;6:187.
[6] Pan Y, Cai W, Cheng Q, et al. Association between anxiety and hypertension: a systematic review and meta-analysis of epidemiological studies. Neuropsychiatr Dis Treat 2015;11:1211–30.
[7] Atlantis E, Fahey P, Cochrane B, et al. Bidirectional associations between clinically relevant depression or anxiety and COPD: a systematic review and meta-analysis. Chest 2013;144:766–77.
[8] Popa SL, Dumitrascu DL. Anxiety and IBS revisited: ten years later. J Gastrointest Med 2015;88:253–7.
[9] Rachner TD, Kosla S, Hofbauer LC. Osteoporosis: now and the future. Lancet 2011;377:1276–87.
[10] Yang NP, Deng CY, Chou YJ, et al. Estimated prevalence of osteoporosis from a Nationwide Health Insurance database in Taiwan. Health Policy 2006;75:329–37.
[11] Samelson EJ, Hannan MT. Epidemiology of osteoporosis. Curr Rheumatol Rep 2006;8:76–83.
[12] Yang Y, Du F, Ye W, et al. Inpatient cost of treating osteoporotic fractures in mainland China: a descriptive analysis. Clinicocon Outcomes Res 2015;7:205–12.
[13] Loters FJ, van den Bergh JP, de Vries F, et al. Current and Future Incidence and Costs of Osteoporosis-Related Fractures in The Netherlands; Combining Claims Data with BMD Measurements. Calcif Tissue Int 2016;98:235–43.
[14] Clark MK, Sowers MF, Dekordi F, et al. Bone mineral density and fractures among alcohol-dependent women in treatment and in recovery. Osteoporos Int 2003;14:396–403.
[15] Jayasinghe Y, Grover SR, Zacharin M. Current concepts in bone and reproductive health in adolescents with anorexia nervosa. BJOG 2008;115:304–15.
[16] Kishimoto T, De Hart M, Carlson HE, et al. Osteoporosis and fracture risk in people with schizophrenia. Curr Opin Psychiatry 2012;25:815–29.
[17] Williams LJ, Bjerkoset O, Langhammer A, et al. The association between depressive and anxiety symptoms and bone mineral density in the general population: the HUNT Study. J Affect Disord 2011;131:164–71.
[18] Vogelzangs N, Beekman AT, de Jonge P, et al. Anxiety disorders and inflammation in a large adult cohort. Transl Psychiatry 2015;5:e249.
[19] Pitasvos C, Panagotakos DB, Papageorgiou C, et al. Anxiety in relation to inflammation and coagulation markers, among healthy adults: the ATTICA study. Atherosclerosis 2006;185:320–6.
[20] O’Donovan A, Hughes BM, Slavich GM, et al. Clinical anxiety, cortisol and interleukin-6: evidence for specificity in emotion-biology relationships. Brain Behav Immun 2010;24:1074–7.
[21] Duggan SN, Purcell C, Kilbane M, et al. An association between abnormal bone turnover, systemic inflammation, and osteoporosis in patients with chronic pancreatitis: a case-matched study. Am J Gastroenterol 2015;110:336–45.
[22] Alves CH, Farrell E, Vis M, et al. Animal Models of Bone Loss in Inflammatory Arthritis: from Cytokines in the Bench to Novel Treatments for Bone Loss in the Bedside-a Comprehensive Review. Clin Rev Allergy Immunol 2015.
[23] Haugeberg G, Bennett AN, McGonagle D, et al. Bone loss in very early inflammatory back pain in undifferentiated spondyloarthropathy: a 1-year observational study. Ann Rheum Dis 2010;69:1364–6.
[24] Yang C, McCoy K, Davis JL, et al. NIK stabilization in osteoclasts results in osteoporosis and enhanced inflammatory osteolysis. PLoS One 2010;5:e15383.
[25] Blaufranc JM, Celano CM, Januzzi JL. The relationship between depression, anxiety, and cardiovascular outcomes in patients with acute coronary syndromes. Neuropsychiatr Dis Treat 2010;6:123–36.
[26] Liukkonen T, Rasanne P, Jokelanen I, et al. The association between anxiety and C-reactive protein (CRP) levels: results from the Northern Finland 1966 birth cohort study. Eur Psychiatry 2011:26:363–9.
[27] Koh JM, Khandh YH, Jung CH, et al. Higher circulating hsCRP levels are associated with lower bone mineral density in healthy pre- and postmenopausal women: evidence for a link between systemic inflammation and osteoporosis. Osteoporos Int 2005;16:1263–71.
[28] Lacatav P, Farías ML. Osteoporosis and inflammation. Arq Bras Endocrinol Metabol 2010;54:123–32.
[29] Lenze EJ, Mantella RC, Shi P, et al. Elevated cortisol in older adults with generalized anxiety disorder is reduced by treatment: a placebo-controlled evaluation of escitalopram. Am J Geriatr Psychiatry 2011;19:482–90.
[30] Mantella RC, Butters MA, Amico JA, et al. Salivary cortisol is associated with diagnosis and severity of late-life generalized anxiety disorder. Psychoneuroendocrinology 2008;33:773–81.
[31] Chaudieu I, Beluche I, Norton J, et al. Abnormal reactions to environmental stress in elderly persons with anxiety disorders: evidence from a population study of diurnal cortisol changes. J Affect Disord 2008;106:307–13.
[32] Chodini I, Scillitani A. Role of cortisol hypersecretion in the pathogenesis of osteoporosis. Recent Prog Med 2008;99:309–13.
[33] Orosa B, Garcia S, Conde C. The autotaxin-lysophosphatidic acid pathway in pathogenesis of rheumatoid arthritis. Eur J Pharmacol 2013;765:228–33.
[34] Wheeler NA, Lister JA, Fuss B. The autotaxin-lysophosphatidic acid axis modulates histone acetylation and gene expression during oligodendrocyte differentiation. J Neurosci 2015;35:11399–414.

[35] Santos-Nogueira E, Lopez-Serrano C, Hernandez J, et al. Activation of lysophosphatidic acid receptor type 1 contributes to pathophysiology of spinal cord injury. J Neurosci 2015;35:10224–35.

[36] Kishimoto T, Ohke M, Ozaki S, et al. Recurrence of the acute respiratory distress syndrome in a patient with liver cirrhosis and diabetes mellitus. Nihon Kyobu Shikkan Gakkai Zasshi 1996;34:586–91.

[37] Jeng LB, Cheng MH, Lee WC, et al. Extracorporeal membrane oxygenation therapy for adult respiratory distress syndrome developing post liver transplantation. Transplant Proc 1994;26:2237–8.

[38] Foley TC, Davis CP, Conway PA. Liver transplant recipients. Nihon Kyobu Shikkan Gakkai Zasshi 1996;34:586–91.

[39] Wariaghli G, Mounach A, Achemlal L, et al. Osteoporosis in chronic liver disease: a case-control study. Nihon Kyobu Shikkan Gakkai Zasshi 1996;34:586–91.

[40] Cao L, Zhang Y, Fu Z, et al. Diagnostic value of plasma lysophosphatidic acid levels in ovarian cancer patients: A case-control study and updated meta-analysis. J Obstet Gynaecol Res 2015;41:1951–8.

[41] Chiang CL, Chen SS, Lee SJ, et al. Lysophosphatidic acid induces erythropoiesis through activating lysophosphatidic acid receptor 3. Stem Cells 2011;29:1763–73.

[42] Patsch JM, Burghardt AJ, Yap SP, et al. Increased cortical porosity in type 2 diabetic postmenopausal women with fragility fractures. J Bone Miner Res 2013;28:313–24.

[43] Kinjo M, Setoguchi S, Schneeweiss S, et al. Bone mineral density in patients with depression, anxiety disorders, and metabolic syndrome in a population at risk for type 2 diabetes mellitus. Gen Hosp Psychiatry 2015;37:403.

[44] Sims SM, Panupinthu N, Lapierre DM, et al. Polyunsaturated lysophosphatidic acid as a potential asthma biomarker. Biomark Med 2016;10:123–35.

[45] Ackerman SJ, Park GV, Christopher JW, et al. Polysaturated lysophosphatidic acid induced by trastuzumab emtansine: an antibody-drug conjugate for breast cancer. Cornea 2016;35:1378–80.

[46] Tsuda M, Takano Y, Shigeysu C, et al. Abnormal corneal lesions induced by trastuzumab emtansine: an antibody-drug conjugate for breast cancer. Cornea 2016;35:1378–80.

[47] Takaniya M, Nakamura M, Akimoto M, et al. Multivariate analysis for the estimation of target localization errors in fiducial marker-based radiotherapy. Med Phys 2016;43:1907.

[48] Wu Q, Bencaz AF, Hentz JG, et al. Selective serotonin reuptake inhibitor treatment and risk of fractures: a meta-analysis of cohort and case-control studies. Osteoporos Int 2012;23:365–75.

[49] Lee CW, Liao CH, Lin CL, et al. Increased risk of osteoporosis in patients with depression; a population-based retrospective cohort study. Mayo Clin Proc 2015;90:63–70.

[50] Kinjo M, Setoguchi S, Schneeweiss S, et al. Bone mineral density in subjects using central nervous system-active medications. Am J Med 2005;118:1414.

[51] Williams LJ, Pasco JA, Snaith RL, et al. Psychiatric disorders, psychotropic medication use and falls among women: an observational study. BMC Psychiatry 2015;15:75.